Abstract:Since the outbreak of the pandemic, waves of epidemics caused by severe acute respiratory syndrome coronavirus 2 （SARS-Co V-2） variants that harbor novel mutations have never paused. Globally, it undergoes rapid mutations that involve single-nucleotide polymorphism（SNP） dominantly, whereas ORF1ab and spike genes contain the most of more than 20,000 mutation sites reported within a year （Fang et al.,2021）. Mutations inside spike protein are highly concerned for their potential impact on viral transmissibility and immune evasion, as spike protein is responsible for the interaction with the viral receptor angiotensin-converting enzyme 2 （ACE2） to mediate viral entry to the target cells. D614G identified in early 2020 is a globally dominant mutation （Korber et al., 2020）. In late 2020, several variants were reported, which had caused continental and eventually worldwide epidemics. These notable variants include B.1.1.7 lineage （501Y.V1,Variant of Concern [VOC] 202012/01）, 501Y.V2 variant （known as B.1.351 lineage）, and P.1 lineage （also named 501Y.V3）. In comparison with the D614G and D614 lineages identified in early 2020, they contain a large number of mutations within spike protein （Fig. 1）.

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development